Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19

INTERVENTION: Intervention 1: Intervention group: Capsule Umnifenovir 100 mg, 2 capsuls every 6 hours, for 7 days. (In addition to routine treatment according to the latest national guideline for the treatment of new corona‐virus). Intervention 2: Control group: routine treatment according to the latest national guideline for the treatment of new corona‐virus. CONDITION: COVID‐19. ; Covid‐19 U07.1 PRIMARY OUTCOME: Respiratory symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire. Respiratory symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer. Respiratory symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: pulse oxymetery device. SECONDARY OUTCOME: Adverse Effects. Timepoint: daily monitoring, but the before the intervention initiation (baseline) and day 7 results will recorded on designed checklist. Method of measurement: questionnaire, clinical examination. Inflammatory biomarker level changes (including interleukin 1, interleukin 6, TNF alpha). Timepoint: before the intervention initiation (baseline), then at day 7. Method of measurement: Elisa kit for Human. Lab tests changes. Timepoint: daily monitoring, but the before the intervention initiation (baseline) and day 7 results will recorded on designed checklist. Method of measurement: blood sample, laboratory analysis. Mortality rate. Timepoint: day 14 of intervention initiation. Method of measurement: questionnaire. Radiologic finding changes in Lung CT‐scan. Timepoint: before the intervention initiation (baseline), then at day 14. Method of measurement: Lung CT‐scan. INCLUSION CRITERIA: age >18 years The patient have written consciously and freely consent to participate in the study. Confirmed diagnosis of COVID‐19, with Laboratory (RT‐PCR) confirmation. Confirmed diagnosis of COVID‐19, with lung CT‐Scan result, which is typical for COVID‐19 pulmonary involvement. O2 saturation at rest in ambient air =93%